The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to halt the sale and production of off-brand products that many patients in ...

If you're following the GLP-1 (Ozempic and other prescription weight-loss medications) scene, you may have read that the FDA ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

Zepbound only comes as a brand-name drug. It’s not currently available in a generic version. A generic contains an exact copy of the active drug in a brand-name medication but tends to cost less.

Attorney James Gourley details the many legal issues surrounding the GLP-1 drug market and offers advice to companies on how ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

President Donald Trump has signed a sweeping executive order setting a 30-day deadline for drugmakers to lower the cost of ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference.

A study, published Sunday in the New England Journal of Medicine, found tirzepatide users lost about 20% of their body weight, whereas those on semaglutide lost about 14% over a 72-week period.

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

The SURMOUNT-5 trial, published over the weekend in the New England Journal of Medicine and presented at the European Congress on Obesity, showed that treatment with tirzepatide (Zepbound; Eli Lilly) ...